182 related articles for article (PubMed ID: 38022678)
1. Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes.
Kalaitsidou M; Moon OR; Sykorova M; Bao L; Qu Y; Sukumaran S; Valentine M; Zhou X; Pandey V; Foos K; Medvedev S; Powell DJ; Udyavar A; Gschweng E; Rodriguez R; Dudley ME; Hawkins RE; Kueberuwa G; Bridgeman JS
Front Immunol; 2023; 14():1256491. PubMed ID: 38022678
[TBL] [Abstract][Full Text] [Related]
2. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
3. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
4. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
5. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
[TBL] [Abstract][Full Text] [Related]
6. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
7. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
[TBL] [Abstract][Full Text] [Related]
8. Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy.
Olguín-Contreras LF; Mendler AN; Popowicz G; Hu B; Noessner E
Front Immunol; 2021; 12():750478. PubMed ID: 34912334
[TBL] [Abstract][Full Text] [Related]
9. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
10. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
11. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.
Santegoets SJ; Turksma AW; Suhoski MM; Stam AG; Albelda SM; Hooijberg E; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; Powell DJ; June CH; de Gruijl TD
J Transl Med; 2013 Feb; 11():37. PubMed ID: 23402380
[TBL] [Abstract][Full Text] [Related]
12. T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.
Willemsen RA; Ronteltap C; Chames P; Debets R; Bolhuis RL
J Immunol; 2005 Jun; 174(12):7853-8. PubMed ID: 15944290
[TBL] [Abstract][Full Text] [Related]
13. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
14. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
Finney HM; Akbar AN; Lawson AD
J Immunol; 2004 Jan; 172(1):104-13. PubMed ID: 14688315
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
[TBL] [Abstract][Full Text] [Related]
16. In situ expression of B7 and CD28 receptor families in human malignant melanoma: relevance for T-cell-mediated anti-tumor immunity.
Denfeld RW; Dietrich A; Wuttig C; Tanczos E; Weiss JM; Vanscheidt W; Schöpf E; Simon JC
Int J Cancer; 1995 Jul; 62(3):259-65. PubMed ID: 7543078
[TBL] [Abstract][Full Text] [Related]
17. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
[TBL] [Abstract][Full Text] [Related]
18. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
19. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL.
Collins MA; Jung IY; Zhao Z; Apodaca K; Kong W; Lundh S; Fraietta JA; Kater AP; Sun C; Wiestner A; Melenhorst JJ
Cancer Res Commun; 2022 Sep; 2(9):1089-1103. PubMed ID: 36922932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]